Cargando…

Updates in IDH-Wildtype Glioblastoma

Glioblastoma is the most aggressive primary brain tumor with a poor prognosis. The 2021 WHO CNS5 classification has further stressed the importance of molecular signatures in diagnosis although therapeutic breakthroughs are still lacking. In this review article, updates on the current and novel ther...

Descripción completa

Detalles Bibliográficos
Autores principales:	Melhem, Jawad M., Detsky, Jay, Lim-Fat, Mary Jane, Perry, James R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9154038/ https://www.ncbi.nlm.nih.gov/pubmed/35641844 http://dx.doi.org/10.1007/s13311-022-01251-6

Ejemplares similares

The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma
por: Diplas, Bill H., et al.
Publicado: (2018)

Intravoxel incoherent motion (IVIM) modeling of diffusion MRI during chemoradiation predicts therapeutic response in IDH wildtype glioblastoma
por: Maralani, Pejman Jabehdar, et al.
Publicado: (2021)

Association of hyperglycemia and molecular subclass on survival in IDH-wildtype glioblastoma
por: Liu, Elisa K, et al.
Publicado: (2022)

Glioblastoma, IDH-wildtype: A New Association with IgM Paraproteinaemic Neuropathy?
por: Lewis, Dana M., et al.
Publicado: (2022)

Pleiotropy of PP2A Phosphatases in Cancer with a Focus on Glioblastoma IDH Wildtype
por: Kashani, Elham, et al.
Publicado: (2022)

GEN-13 FIREWORK PATTERN OF CANCER GENESIS FOR GLIOBLASTOMA, IDH-WILDTYPE
por: Yoon, Seon-Jin, et al.
Publicado: (2019)

Gene Expression Profiling Stratifies IDH-Wildtype Glioblastoma With Distinct Prognoses
por: Liu, Yu-Qing, et al.
Publicado: (2019)

Prognostic Analysis of the IDH1 G105G (rs11554137) SNP in IDH-Wildtype Glioblastoma
por: Saaid, Ayoub, et al.
Publicado: (2022)

Glioblastoma, IDH-wildtype with leptomeningeal metastasis to Meckel’s cave: A case report
por: Murata, Toshiki, et al.
Publicado: (2022)

Distribution and favorable prognostic implication of genomic EGFR alterations in IDH ‐wildtype glioblastoma
por: Higa, Nayuta, et al.
Publicado: (2022)

Location-Dependent Patient Outcome and Recurrence Patterns in IDH1-Wildtype Glioblastoma
por: Jungk, Christine, et al.
Publicado: (2019)

Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patients
por: Radke, Josefine, et al.
Publicado: (2019)

Co-expression of cancer driver genes: IDH-wildtype glioblastoma-derived tumorspheres
por: Yoon, Seon-Jin, et al.
Publicado: (2020)

Initial Treatment of IDH-Wildtype Glioblastoma in Adults Older Than 70 Years
por: Bao, Jing, et al.
Publicado: (2023)

ADC, D, f dataset calculated through the simplified IVIM model, with MGMT promoter methylation, age, and ECOG, in 38 patients with wildtype IDH glioblastoma
por: Maralani, Pejman Jabehdar, et al.
Publicado: (2021)

Newly Diagnosed IDH-Wildtype Glioblastoma and Temporal Muscle Thickness: A Multicenter Analysis
por: Wende, Tim, et al.
Publicado: (2021)

Genetic and epigenetic landscape of IDH-wildtype glioblastomas with FGFR3-TACC3 fusions
por: Mata, Douglas A., et al.
Publicado: (2020)

EGFL7 expression profile in IDH-wildtype glioblastomas is associated with poor patient outcome
por: da Costa, Bruno Henrique Bressan, et al.
Publicado: (2022)

XGBoost Improves Classification of MGMT Promoter Methylation Status in IDH1 Wildtype Glioblastoma
por: Le, Nguyen Quoc Khanh, et al.
Publicado: (2020)

MPC-02 Prognostic effects of molecular factors in elderly patients with IDH-wildtype Glioblastomas
por: Fukai, Junya, et al.
Publicado: (2020)

Prognostic significance of baseline thyroid variables in IDH-wildtype glioblastoma patients treated with regorafenib
por: Lawson McLean, Aaron
Publicado: (2023)

HGG-56. EXTENSIVE MOLECULAR HETEROGENEITY WITHIN H3-/IDH-WILDTYPE PEDIATRIC GLIOBLASTOMA
por: Blattner-Johnson, Mirjam, et al.
Publicado: (2020)

Immuno-phenotyping of IDH-mutant grade 3 astrocytoma and IDH-wildtype glioblastoma reveals specific differences in cells of myeloid origin
por: Raghavan, Jayashree V., et al.
Publicado: (2021)

Differential Predictors and Clinical Implications Associated With Long-Term Survivors in IDH Wildtype and Mutant Glioblastoma
por: Jiang, Haihui, et al.
Publicado: (2021)

Does positive MGMT methylation outbalance the limitation of subtotal resection in glioblastoma IDH-wildtype patients?
por: Mareike, Müller, et al.
Publicado: (2021)

Topographical Mapping of 436 Newly Diagnosed IDH Wildtype Glioblastoma With vs. Without MGMT Promoter Methylation
por: Incekara, Fatih, et al.
Publicado: (2020)

Prospective genomically guided identification of “early/evolving” and “undersampled” IDH-wildtype glioblastoma leads to improved clinical outcomes
por: Zhang, Yalan, et al.
Publicado: (2022)

Pattern of Recurrence of Glioblastoma Versus Grade 4 IDH-Mutant Astrocytoma Following Chemoradiation: A Retrospective Matched-Cohort Analysis
por: Stewart, James, et al.
Publicado: (2022)

Transcriptional Profiling of a Patient-Matched Cohort of Glioblastoma (IDH-Wildtype) for Therapeutic Target and Repurposing Drug Identification
por: Roddy, Aideen C., et al.
Publicado: (2023)

DNA-methylome-assisted classification of patients with poor prognostic subventricular zone associated IDH-wildtype glioblastoma
por: Adeberg, Sebastian, et al.
Publicado: (2022)

Carnosine selectively inhibits migration of IDH-wildtype glioblastoma cells in a co-culture model with fibroblasts
por: Oppermann, Henry, et al.
Publicado: (2018)

The Influence of Gene Aberrations on Survival in Resected IDH Wildtype Glioblastoma Patients: A Single-Institution Study
por: Kalita, Ondrej, et al.
Publicado: (2021)

Astrocytoma and IDH1-Wildtype Glioblastoma (GBM) Cells Colonize Tumor Vessels and Deploy Vascular Mimicry
por: Maraqah, Haitham H., et al.
Publicado: (2023)

The Association Between the Extent of Glioblastoma Resection and Survival in Light of MGMT Promoter Methylation in 326 Patients With Newly Diagnosed IDH-Wildtype Glioblastoma
por: Incekara, Fatih, et al.
Publicado: (2020)

Magnetic resonance spectroscopic correlates of progression free and overall survival in “glioblastoma, IDH-wildtype, WHO grade-4”
por: Sacli-Bilmez, Banu, et al.
Publicado: (2023)

Re-irradiation of recurrent IDH-wildtype glioblastoma in the bevacizumab and immunotherapy era: Target delineation, outcomes and patterns of recurrence
por: Christ, Sebastian M., et al.
Publicado: (2023)

Methylation class oligosarcoma may encompass IDH-wildtype gliomas
por: Ebrahimi, Azadeh, et al.
Publicado: (2022)

PDPN contributes to constructing immunosuppressive microenvironment in IDH wildtype glioma
por: Wang, Xuya, et al.
Publicado: (2022)

CBMS-1 Targeting amino acid metabolic vulnerabilities in IDH-mutant and IDH-wildtype gliomas
por: Ohba, Shigeo, et al.
Publicado: (2021)

A tailored next‐generation sequencing panel identified distinct subtypes of wildtype IDH and TERT promoter glioblastomas
por: Higa, Nayuta, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tm6kaonngsluo9j991ucvsgn20